Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine

Despite current advancements in chemotherapy, immunotherapy and targeted treatments, the potential for major adverse cardiovascular events, regardless of previous cardiac history, persists. Scoring systems, such as the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) risk a...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuel, Younan, Babu, Aswin, Karagkouni, Foteini, Ismail, Ayden, Choi, Sunyoung, Boussios, Stergios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605822/
https://www.ncbi.nlm.nih.gov/pubmed/37886969
http://dx.doi.org/10.3390/cimb45100526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605822/
https://www.ncbi.nlm.nih.gov/pubmed/37886969
http://dx.doi.org/10.3390/cimb45100526

Ejemplares similares